ArticleEMBO molecular medicine2020
Can artificial intelligence identify effective COVID-19 therapies?
Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Harnessing the power of artificial intelligence for human living organoid research.Bioactive materials · 2024Review
- Paving New Roads UsingIranian journal of pharmaceutical research : IJPR · 2022Review
- Machine learning insights concerning inflammatory and liver-related risk comorbidities in non-communicable and viral diseases.World journal of gastroenterology · 2022Review
- Application Progress of Organoids in Colorectal Cancer.Frontiers in cell and developmental biology · 2022Review
- A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019.Journal of personalized medicine · 2021Review
- Role of rehabilitation amidst the COVID-19 pandemic: a review.Journal of translational medicine · 2021Review
- Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19.Pathogens (Basel, Switzerland) · 2021Review
- Applications of artificial intelligence in battling against covid-19: A literature review.Chaos, solitons, and fractals · 2021Review
- Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.Computational and structural biotechnology journal · 2021Review
- Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models.Frontiers in cell and developmental biology · 2021Review
- JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.Science advances · 2021Observational
- Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).The international journal of occupational and environmental medicine · 2020Review
- Can artificial intelligence identify effective COVID-19 therapies?EMBO molecular medicine · 2020Article
- Insights in paediatric virology during the COVID-19 era (Review).Medicine internationalReview
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence-assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID-19. Using liver organoids infected with SARS-CoV-2, they confirm dual antiviral and anti-inflammatory activities and show that its administration in four COVID-19 patients is correlated with disease improvement, paving the way for more rigorous placebo-controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.